INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therap

BOCA RATON, Fla. , July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"),

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2

Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Re

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Re

The Department of Defense–funded study; entitled: "Inhibition of Soluble TNF Mitigates Traumatic

The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease

Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and co

Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and co

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Prog

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path f

MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions co

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0. 0028; d=0. 4

Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage bi

BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotec

Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology l

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1

Stocks That Hit 52-Week Lows On Monday